Day One

• Exploring how developers are advancing small-scale, high-throughput optimisation systems to streamline phage production and de-risk clinical manufacturing
• Understanding the critical parameters that define yield and quality – from oxygen and pH control to seeding and harvest timing – and how these influence capsid integrity, potency, and downstream formulation
• Examining how partnerships between academic platforms, SMEs, and contract manufacturers can enable early-stage innovators to generate robust data packages without the prohibitive costs of full GMP infrastructure

• Strategies for translating lab-scale processes into GMP production without compromising quality or yield
• Practical insights into host strain selection, propagation and purification workflows that scale
• How to manage cost of goods and production timelines while maintaining reproducibility across batches

As the global phage community comes together once again for this year’s summit, this dedicated session offers a unique opportunity to reconnect with familiar faces and meet many new ones too. Join peers spanning biotech, academia, healthcare and policy to strengthen collaborations, spark new ideas and build relationships that will continue driving the field forward long after the summit.

• Outlining how Intralytix evolved from its origins in human therapeutic phage development to becoming a global pioneer in food safety and environmental biocontrol, leveraging these commercial successes to re-enter the human health space with multiple clinical-stage phage therapy programs
• Examining the ongoing technical and regulatory challenges facing the field, including the identification of potent therapeutic phages, ensuring scalability, and meeting cGMP standards under 21 CFR 111/117 and 210/211 to bridge discovery and clinical translation
• Showcasing Intralytix’s proprietary PhageSelector™ and PhageEngine™ platforms, which integrate high-throughput screening, data science, and AI to refine phagehost pairing, guide cocktail formulation, and streamline scale-up for therapeutic and microbiome-modulating applications

• Building a clinical development framework for orally administered phage therapeutics targeting cholera prevention in low and middle income countries
• Designing human challenge models to establish clinical proof of concept and regulatory confidence for outbreak ready phage formulations
• Bridging regulatory, manufacturing and market access considerations to enable scalable and sustainable deployment of phage therapies as public health tools

• Exploring the rise of phage-derived enzymes and actives in consumer health, hygiene and household applications
• Overcoming regulatory grey zones that limit commercialisation across cosmetics, OTC and household sectors
• Scaling production, ensuring stability and building viable business models for mainstream consumer adoption

• Investigate the potential of methanogen-specific phages to selectively modulate archaeal populations in the rumen, reducing methane emissions and improving feed efficiency in livestock
• Assess how phage-driven shifts in the rumen microbial community affect overall microbiome stability, nutrient cycling, and greenhouse gas production
• Explore parallels between methanogen–phage interactions in animals and the human gut, exploring the potential for phage therapies for dysbiosis-associated conditions such as inflammation and metabolic disorders

• Demonstrating field-proven success in reducing bacterial burden and boosting yield across crops and livestock
• Overcoming farmer hesitancy through clear ROI, reliable trial design, and repeatable real-world validation
• Establishing scalable business models and strategic partnerships that drive durable adoption from farm to food chain

Join the phage community for an interactive session exploring pioneering research, breakthrough phage technologies, and real-world solutions to accelerate access and adoption. Share your work, exchange ideas, connect with peers, and help shape the future of bacteriophage therapy. See full T&Cs online for eligibility.

• Exploring how lysins deliver rapid, contact-based bacterial killing with no observed resistance, whilst building strategies for de-immunising capsid proteins and engineering less reactive formulations
• Learning from past clinical experiences to design smarter trials and overcome funding setbacks
• Showcasing how computational engineering and compassionate use models are unlocking a viable path forward for lysin therapeutics

• Presenting results of FHD clinical study and clinical development plan for SNIPR001, a cocktail of engineered, CRISPR-armed phages targeting E. coli
• Discussing other uses of SNIPR001 based on in vivo preclinical data and a case study
• Outlining the critical steps toward building a regulatory and clinical evidence base that can support the first approvals of engineered phage products

• Addressing CMC, stability, and delivery challenges unique to synthetic or proteinbased antimicrobials
• Aligning development pathways with evolving regulatory expectations for nontraditional therapeutics
• Ensuring robust preclinical models and manufacturing scalability to accelerate realworld clinical adoption